A Phase 1/2 Safety And Pharmacokinetic Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Metastatic Hormone Refractory Prostate Cancer (HRPC).
Phase of Trial: Phase I/II
Latest Information Update: 25 Aug 2011
At a glance
- Drugs Docetaxel; Prednisone; Sunitinib
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 11 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 May 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.